Liquidia Co. (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Analysts

Liquidia Co. (NASDAQ:LQDA) has received an average rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $24.00.

Several analysts have issued reports on the stock. Scotiabank began coverage on shares of Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target for the company. BTIG Research decreased their price target on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Bank of America dropped their price target on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, November 14th.

Liquidia Stock Performance

Shares of LQDA opened at $10.15 on Friday. The business has a 50-day moving average of $10.55 and a 200 day moving average of $11.42. The firm has a market cap of $859.10 million, a P/E ratio of -6.23 and a beta of 0.21. Liquidia has a fifty-two week low of $6.60 and a fifty-two week high of $16.99.

Insiders Place Their Bets

In related news, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the transaction, the insider now directly owns 207,383 shares in the company, valued at $2,304,025.13. The trade was a 1.08 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Caligan Partners Lp acquired 150,000 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were bought at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the acquisition, the director now owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This represents a 2.19 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 21,551 shares of company stock worth $236,021. 30.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Farallon Capital Management LLC acquired a new position in shares of Liquidia in the 1st quarter valued at about $30,311,000. Whitefort Capital Management LP increased its stake in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after acquiring an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after acquiring an additional 230,820 shares during the last quarter. Anson Funds Management LP acquired a new position in Liquidia in the third quarter valued at about $1,764,000. Finally, Sapient Capital LLC purchased a new stake in Liquidia during the third quarter worth about $1,336,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).